The costs of treating lung cancer

Kliknij autora aby wyszukać wszystkie publikowane przez niego artykuły:
Ilona Zaręba, Edyta Rysiak, Renata Zaręba, Joanna Stelmaszewska, Alina Cywoniuk, Magdalena Jakuc, Izabela Prokop, Hubert Janowski

3 (44) 2015 s. 205–208
Click to return to issue contents
205_3_44_2015.pdf
Digital version of article (in PDF file)

Fraza do cytowania: Zaręba I., Rysiak E., Zaręba R., Stelmaszewska J., Cywoniuk A., Jakuc M., Prokop I., Janowski H. The costs of treating lung cancer. Polski Przegląd Nauk o Zdrowiu. 2015;3(44):205–208.

The most common cancer in Poland is lung cancer. Annually diagnosed about 16 000 cases among men and about 6,000 among women. Lung cancer is a malignant tumor. It is the cause of many deaths among the entire population of the world. Lung cancer in the first period develops without symptoms of the disease, which is associated with slow development of cancer itself. Individual symptoms appear gradually and unevenly. This is a major problem associated with early detection and diagnosis. In recent years, financial expenditure incurred for the treatment of patients diagnosed with lung cancer increases dramatically. The increase in costs for diagnosis and treatment of this cancer due to the increasing number of patients and the introduction of modern treatment standards. However, lack of routine and low efficiency of preventive actions have a significant influence on the ever growing problem. Increased amounts of lung cancer generates high financial outlay society.

Key words: lung cancer, medical cost, pharmacoeconomics.



Copyright © 1989–2024 Polish Review of Health Sciences. All rights reserved.